{"id":"W4304474516","doi":"10.1200/jco.21.02508","title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute for Health and Care Research; Cancer Research UK","keywords":"Pembrolizumab; Medicine; Internal medicine; Hazard ratio; Oncology; Head and neck squamous-cell carcinoma; Chemotherapy; Interquartile range; Cetuximab; Head and neck cancer; Population; Radiation therapy; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003996473,0.0007062602,0.001608269,0.0002567811,0.0002092499,0.0008314502,0.0007003195,0.0006002649,0.001717444],"category_scores_gemma":[0.001935593,0.0002939796,0.001971894,0.0004963947,0.000297915,0.000665623,0.0003561844,0.001349241,0.0004337123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008983921,"about_ca_system_score_gemma":0.0009784395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001255782,"about_ca_topic_score_gemma":0.003338982,"domain_scores_codex":[0.9992709,0.0003942453,0.00005869291,0.0001018399,0.0001016299,0.00007270882],"domain_scores_gemma":[0.9988245,0.0002384752,0.0004980433,0.0001333228,0.0001233507,0.0001822878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6351761,0.01037137,0.07782759,0.004676389,0.02005145,0.0002608611,0.0002428624,0.003309913,0.0195926,0.000288729,0.01302863,0.2151735],"study_design_scores_gemma":[0.4169755,0.213849,0.3129088,0.0007352715,0.02450801,0.001118193,0.0002185165,0.002534139,0.006463116,0.0004139643,0.02018108,0.00009447067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9704297,0.022132,0.0005776257,0.0004691534,0.0001418945,0.0006442885,0.003737023,0.00005874569,0.001809364],"genre_scores_gemma":[0.9830506,0.008119136,0.000787511,0.0008094697,0.000160356,0.0007445576,0.004973339,0.00002851073,0.001326469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003996473,"threshold_uncertainty_score":0.02113563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1305832615829773,"score_gpt":0.4718791313295498,"score_spread":0.3412958697465725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}